James Helliwell, MD
President and Chief Executive Officer
Eupraxia founder James Helliwell holds a medical degree from the University of British Columbia (UBC), and Fellowship Certification in Cardiac Anesthesiology and transplantation, and board certification in Perioperative Echocardiography. Prior to founding Eupraxia, he held a clinical practice at a quaternary academic cardiac center in St. Paul’s Hospital, Vancouver. He also served as Clinical Assistant Professor at the University of British Columbia in the Department of Anesthesiology, Pharmacology and Therapeutics.
Dr. Helliwell has many granted patents to his name and successfully created a medical device, built a company around it and sold it to a large strategic partner. He has also been actively involved in other successful start-ups in the medical technology space. As a physician-entrepreneur with an active interest in medical and policy leadership, most recently the presidency of the provincial body guiding anesthesiology care in British Columbia. His leadership of Eupraxia is a natural extension, allowing use of his scientific and administrative knowledge to lead a progressive company dedicated to providing patients with precision delivery technology and innovative pharmacologic treatments to relieve suffering and improve lives.
Amanda Malone, PhD
Chief Scientific Officer
Co-founder Dr. Amanda Malone has worked on the development of drug delivery systems for almost 15 years. Dr. Malone has worked on multiple types of complex sustained release products including: parenteral injections for the treatment and prevention of a wide variety of diseases, intravaginal rings releasing multiple drugs for the prevention of HIV, anti-infective films for the prevention of surgical site infections, topical co-drugs for the treatment of herpes, and punctal plugs for the treatment of chronic eye conditions.
Dr. Malone has authored 15 publications related to bone function and polymer-based drug delivery, as well as 5 distinct patent families with patents granted in the US, EU and Oceania. She has been a Principal Investigator on over $11M in grant funding from both the US and Canadian governments and was a National Science Foundation Fellow. While at Eupraxia, she has guided the scientific programs through pre-clinical and manufacturing development, the regulatory process in multiple jurisdictions and into the clinic. Prior to joining Eupraxia, Dr. Malone was the VP and COO of a drug-delivery focused biotech, Auritec Pharmaceuticals. She graduated with High Honors from Harvey Mudd College in Claremont, California with a degree in Engineering, received her master’s degree in Mechanical Engineering from Stanford University and was the inaugural PhD student in Stanford’s Bioengineering Department.
Alex Rothwell, B.Ch.E., M.B.A
Chief Financial Officer & Chief Operating Officer
Prior to moving to Victoria, BC, Alex was President & Executive Director of Macquarie Capital Markets Canada in Toronto. There he had management and P&L responsibility for all operations in equities (sales, trading, research, risk management, finance, IT, HR, legal, regulatory & compliance) with staff in Toronto, Montreal, Calgary, Vancouver, New York and London. While in this role, he also worked closely with the firm’s corporate clients to advise them on their growth & acquisition strategies, associated funding requirements, and to manage their engagement with the institutional investor community. He began his finance career in 1995 with UBS Canada advising US hedge funds on their trading strategies. In addition to his hedge funds expertise, he has an extensive knowledge of, and connections to, the global network of institutional funds that finance Canadian companies and are active in Canadian equity markets.
Mr. Rothwell has an MBA from the Ivey School of Business (1995) and holds a Bachelor of Chemical Engineering from McGill University (1991).
Vik Peck, BSc/BJourn, PMP
Vice-President, Program Management, Regulatory and Quality Affairs
Vik Peck has almost 25 years of experience in global pharmaceutical development. She has directed large, multinational programs across a wide variety of indications and developmental stages – from business case analysis through formulation/manufacturing, nonclinical/clinical development, global registration, market launch and lifecycle of both prescription and consumer health care products. Her current role includes overall program direction, as well as oversight of regulatory and quality affairs.
Ms. Peck joined Eupraxia from Vifor Pharma, an international pharmaceutical company with headquarters in Zurich, where she served as Head of Global Project Management and directed flagship products and initiatives. Most recently, this included the development, registration and successful launch of Velphoro® (a prescription phosphate binder) in 30+ countries, and oversight of a global virtual team of project managers. She also established and led the Alliance Management function for the company’s co-development activities in Asia-Pacific. Until its acquisition by Vifor, Ms. Peck worked for Aspreva Pharmaceuticals, providing program management oversight for development of Cellcept® in lupus nephritis and orphan indications. Earlier in her career, Ms. Peck held both operational and management positions in a global contract research organization. Ms. Peck holds a Combined Honours degree in Biology and Journalism from Carleton University and is a longstanding, certified Project Management Professional.
Murray Webb, PhD
Vice President, Translational Science
Dr. Webb has over 25 years of drug discovery and development experience in both industrial and academic settings, with a focus on the conduct and management of translational preclinical studies supporting the entry of novel drugs into clinical trials. This expertise includes an extensive background in vivo efficacy, pharmacodynamics, pharmacokinetic studies, ADME/biodistribution studies, non-GLP and GLP toxicology studies, drug combination studies and natural products.
Dr. Webb also has expertise in the regulatory requirements for novel oncology in clinical testing and has initiated and managed Phase I and II cancer clinical trials. Collectively, Dr. Webb has more than 90 published research articles, including 32 patents (seven granted) and is the co-inventor of Marqibo®, FDA approved for the treatment of acute lymphoblastic leukemia, plus five novel drugs in advanced preclinical and clinical testing by three different US-based companies.
Nicola Price, BSc
Vice President, Clinical Development
Nicola Price is a seasoned clinical development professional with more than 20 years of experience in designing, managing and executing clinical trials. She has held operational and management roles in large pharma (Pfizer and AstraZeneca) and biotech companies. Prior to joining Eupraxia, Ms Price was Director of Clinical Development at Xenon Pharmaceuticals, where she was responsible for the management and oversight of Clinical and Regulatory. Her experience spans all phases of drug development, with a focus on clinical pharmacology to the end of Phase 2. She has experience in multiple therapeutic areas including respiratory, cardiovascular, chronic pain and orphan diseases, as well as a proven track record of developing and maintaining strong relationships with thought leaders, clinical trial investigators and patient advocacy groups. In her current role, Ms Price oversees clinical science, clinical operations and medical affairs.
Nicola received her B.Sc (Hons) in Biological Sciences from the University of Warwick.
Jim Price, MSc
Vice President, Pharmacometrics and Data Analytics
Jim Price has over 20 years of experience in the pharmaceutical industry as a Statistician, Pharmacometrician and mathematical consultant. He has worked in a broad range of therapeutics areas at large pharma (Pfizer and AstraZeneca) and small biotechs, predominantly integrated within early phase and non-clinical research. Over this time he has been pivotal in using modern, advanced data analytical techniques to enable strategic business decisions and optimize the process of drug development; and has ensured a data-driven culture empowered to make informed decisions.
He holds a M.Sc. in Medical Statistics and Information Technology from Leicester University, and a B.Sc. (Hons) in Mathematics and Statistics from the University of Warwick.
Troy Loss, BSc
Senior Director, Chemistry, Manufacturing and Controls
Troy Loss has developed and manufactured drug delivery systems for over 15 years, both at Northern Lipids (now Transferra Nanosciences) and Angiotech Pharmaceuticals. At Northern Lipids, he rose from Manufacturing Associate to GMP Facility Manager and oversaw all operations of their GMP manufacturing facility, which produced sustained release lipid-based formulations. At Angiotech, he contributed to the development of drug coated medical devices and formulations designed for local drug delivery. Prior to joining Angiotech, Mr. Loss worked at Cantest, which performed analytical services for multiple industries. At Cantest, he was responsible for performing routine testing and developing new assays. Mr. Loss received a BSc. (Hon) in Chemistry from the University of British Columbia. At Eupraxia, he oversees the process optimization and manufacturing of our portfolio of products.
Ash Bassett, BCom
Senior Director, Finance
Ash Bassett has over 15 years of finance experience in both public practice and technology startups. In his previous role as Director of Finance at Pulse Energy, he managed the finance and administrative functions of a rapidly growing software development company. This led to the successful acquisition by EnerNOC in late 2014. Since joining Eupraxia in 2016, Ash has developed and overseen all facets of the finance, outsourcing, human resources and information technology functions.
Ash has a Bachelor of Commerce with a major in Accounting & Finance from Curtin University of Technology and also maintains his CPA designation with CPA Australia.